How to Get Testosterone Cypionate in New Hampshire

New Hampshire Allows Telehealth Prescriptions for Testosterone Cypionate

Residents of New Hampshire can legally receive a testosterone cypionate prescription through a telehealth consultation. The state board of medicine permits synchronous audio-video visits for controlled substance prescribing when an established provider-patient relationship exists, which aligns with DEA telemedicine prescribing regulations.

New Hampshire's telehealth framework does not require an initial in-person visit before prescribing Schedule III substances like testosterone cypionate, provided the prescriber conducts a thorough clinical evaluation. This means a patient in Concord, Nashua, or rural Carroll County has equivalent access to a board-certified TRT provider.

The prescriber must review qualifying lab work, take a complete medical history, and assess symptoms consistent with hypogonadism before writing a prescription. Telehealth platforms typically coordinate lab orders through national networks (Quest Diagnostics and Labcorp both operate draw sites across NH), so the process from sign-up to prescription can take fewer than 10 business days. Patients who already have recent lab results (drawn within 60-90 days) may receive a prescription after a single video consultation.

What Labs You Need Before Starting TRT in New Hampshire

A responsible prescriber will order specific blood tests before initiating testosterone cypionate therapy. Skipping labs is a red flag. The Endocrine Society's 2018 clinical practice guideline recommends confirming low testosterone with at least two morning serum total testosterone measurements below 300 ng/dL.

Required baseline labs typically include:

• Total testosterone (drawn between 7:00 and 10:00 AM, fasting preferred)
• Free testosterone or bioavailable testosterone
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
• Complete blood count (CBC) with hematocrit, since testosterone increases erythropoiesis
• Comprehensive metabolic panel (CMP) including liver enzymes
• Lipid panel
• Prostate-specific antigen (PSA) for men aged 40 and older
• Estradiol (E2) as a baseline before therapy

The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that testosterone gel treatment for one year improved sexual function, physical activity, and mood compared to placebo (Snyder et al., NEJM 2016). These trials helped establish the lab thresholds and monitoring protocols that prescribers across New Hampshire now follow.

Once on therapy, follow-up labs are typically drawn at 6-8 weeks, then every 6-12 months. Hematocrit monitoring is non-negotiable: the FDA prescribing information for testosterone cypionate carries a warning about polycythemia risk, with hematocrit levels above 54% requiring dose reduction or therapeutic phlebotomy.

Who Can Prescribe Testosterone Cypionate in New Hampshire

New Hampshire grants prescriptive authority for Schedule III controlled substances to multiple provider types. You are not limited to endocrinologists or urologists.

Medical doctors (MD) and doctors of osteopathy (DO) hold full prescriptive authority. Any licensed physician in New Hampshire can prescribe testosterone cypionate if they determine clinical need. Specialties commonly managing TRT include endocrinology, urology, family medicine, and internal medicine.

Advanced Practice Registered Nurses (APRNs) in New Hampshire have full practice authority under RSA 326-B. This means nurse practitioners can independently evaluate, diagnose hypogonadism, and prescribe testosterone cypionate without physician oversight. NH is a full-practice-authority state for APRNs. This matters for access.

Physician Assistants (PAs) can prescribe controlled substances in New Hampshire under a collaborative agreement with a supervising physician. The PA must have the prescribing of controlled substances included in their scope of practice as defined by that agreement.

All prescribers must hold an active DEA registration and a New Hampshire Controlled Drug Act registration. Patients should verify that their telehealth provider is licensed specifically in New Hampshire, not just in the state where the provider is physically located, since controlled substance prescribing requires state-specific licensure.

503A Compounding Pharmacies in New Hampshire

New Hampshire licenses 503A compounding pharmacies that can prepare testosterone cypionate formulations. These pharmacies operate under a patient-specific prescription and are regulated by the New Hampshire Board of Pharmacy.

A 503A pharmacy compounds medications based on an individual prescription from a licensed prescriber. This differs from 503B outsourcing facilities, which produce larger batches without patient-specific prescriptions. For testosterone cypionate, 503A compounding may offer advantages in specific scenarios:

• Custom concentrations not available in commercial products (e.g., 150 mg/mL instead of the standard 200 mg/mL)
• Alternative carrier oils for patients allergic to cottonseed oil, which is the base in most commercial testosterone cypionate formulations
• Combined formulations when a prescriber orders testosterone cypionate with other compounds

Compounded testosterone cypionate from a 503A pharmacy costs roughly $30-80 per month depending on dose and concentration. Commercial generic testosterone cypionate (200 mg/mL, 10 mL vial) typically runs $40-100 without insurance through major retail pharmacies. GoodRx-type discount cards can reduce the commercial generic price to $25-50 at pharmacies like CVS, Walgreens, and Walmart locations across New Hampshire.

Patients should confirm that any compounding pharmacy they use holds a current New Hampshire Board of Pharmacy license and follows USP 797 sterile compounding standards. The FDA maintains oversight of compounding pharmacies and has issued multiple warning letters to facilities with sterility violations.

Insurance and Cost Considerations in New Hampshire

New Hampshire Medicaid does not cover testosterone cypionate for male hypogonadism. This is a significant barrier for Medicaid-enrolled patients. Private insurance coverage varies by plan, and most commercial insurers will cover generic testosterone cypionate with prior authorization documentation.

Prior authorization for testosterone cypionate typically requires:

• Two documented low testosterone levels drawn in the morning (below the lab's reference range, generally <300 ng/dL)
• ICD-10 diagnosis code E29.1 (testicular hypofunction) or relevant secondary hypogonadism code
• Documentation of symptoms such as fatigue, decreased libido, erectile dysfunction, or loss of muscle mass
• Evidence that contraindications have been ruled out, including prostate cancer, untreated severe sleep apnea, hematocrit above 50% at baseline, and uncontrolled heart failure

The American Urological Association's 2018 guideline on testosterone deficiency specifies that testosterone therapy should not be initiated to improve fertility, as exogenous testosterone suppresses spermatogenesis. Insurers sometimes deny claims when the clinical documentation does not clearly distinguish between fertility treatment and hypogonadism management.

For patients paying out of pocket, testosterone cypionate remains one of the most affordable injectable testosterone formulations. A 10 mL vial of 200 mg/mL generic testosterone cypionate, enough for 10-20 weeks depending on dose, costs $30-80 at most New Hampshire pharmacies.

How Long Until You Receive Testosterone Cypionate in New Hampshire

The timeline from initial decision to first injection depends on several factors. Here is a realistic breakdown.

Days 1-2: Sign up with a telehealth platform or schedule an appointment with a local prescriber. Complete intake forms and medical history questionnaires.

Days 2-5: Get blood drawn at a local lab. Quest Diagnostics operates 12 patient service centers across New Hampshire, and Labcorp has additional locations. Results typically return within 48-72 hours.

Days 5-7: Telehealth video consultation or in-person visit. The prescriber reviews lab results, confirms diagnosis, and writes the prescription if clinically appropriate.

Days 7-10: Prescription sent to a retail pharmacy or 503A compounder. Retail pharmacies can usually fill testosterone cypionate within 24-48 hours. Compounding pharmacies may take 3-5 business days for preparation and shipping.

Patients transferring an existing prescription from another state can expedite this timeline. New Hampshire pharmacies accept transferred controlled substance prescriptions from other states, though the receiving pharmacist must verify the prescription's validity and the prescriber's licensure. A prescription transfer typically adds only 1-2 business days.

The DEA's regulation on Schedule III prescriptions allows up to five refills within six months of the original prescription date. This means once established on therapy, patients do not need a new prescription for each refill cycle, reducing ongoing wait times to zero for routine refills.

Dosing and Administration for Testosterone Cypionate

The FDA-approved prescribing information recommends testosterone cypionate doses of 50-400 mg intramuscularly every 2-4 weeks for male hypogonadism. In clinical practice, most TRT prescribers have moved toward more frequent, lower-dose protocols that produce more stable serum levels.

Modern evidence-based dosing protocols include:

• 100-200 mg intramuscularly once weekly using a 22-25 gauge, 1-inch needle in the vastus lateralis or deltoid
• 50-100 mg subcutaneously twice weekly using a 27-30 gauge, 0.5-inch insulin syringe in abdominal or thigh subcutaneous tissue
• Twice-weekly splitting reduces peak-to-trough fluctuations and may decrease estradiol conversion and hematocrit elevation

A 2017 pharmacokinetic study published in the Journal of the Endocrine Society found that subcutaneous testosterone cypionate injections produced comparable serum testosterone levels to intramuscular injections with lower peak concentrations and reduced injection-site pain (Al-Futaisi et al.). Many New Hampshire prescribers now offer subcutaneous protocols as a first-line option because of patient preference and easier self-administration.

Testosterone cypionate has a half-life of approximately 8 days in depot after intramuscular injection. Steady-state serum levels are typically achieved after 4-5 half-lives, or roughly 5-6 weeks of consistent dosing. Prescribers should not adjust doses based on labs drawn before this steady-state window.

Monitoring and Follow-Up Requirements

Ongoing monitoring is a clinical requirement, not optional. The Endocrine Society guideline recommends the following schedule after initiating testosterone cypionate:

At 6-8 weeks: Total testosterone (drawn at trough, just before next injection), hematocrit, and symptom assessment. Target trough testosterone: 400-700 ng/dL for most patients.

At 3-6 months: Repeat testosterone, hematocrit, PSA (if applicable), lipid panel, and hepatic function. Assess symptom improvement.

Every 6-12 months thereafter: Testosterone, hematocrit, PSA, lipid panel, and CMP. Annual DEXA scan may be warranted in patients with baseline osteopenia.

Hematocrit above 54% requires intervention. Options include dose reduction, switching to more frequent lower-dose injections, or therapeutic phlebotomy. The Testosterone Trials cardiovascular substudy found increased coronary artery plaque volume in testosterone-treated men, which is why cardiovascular risk factor monitoring (blood pressure, lipids, glucose) remains part of responsible TRT management.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, showed that testosterone replacement in men aged 45-80 with hypogonadism and cardiovascular risk factors did not increase the incidence of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months (Lincoff et al., NEJM 2023). This trial prompted the FDA to update the testosterone class labeling to remove the broad cardiovascular warning that had been added in 2015, though monitoring remains standard practice.

Patients using telehealth platforms for TRT in New Hampshire should confirm that their provider coordinates ongoing lab monitoring and dose adjustments, not just the initial prescription.